董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert A. Berman | 男 | Chief Executive Officer and Director | 63 | 58.38万美元 | 4.58 | 2026-03-26 |
| Francis Duhay | 男 | Director | 65 | 7.00万美元 | 0.52 | 2026-03-26 |
| Sanjay Shrivastava | 男 | Director | 58 | 7.50万美元 | 0.30 | 2026-03-26 |
| Matthew M. Jenusaitis | 男 | Director | 64 | 7.50万美元 | 0.32 | 2026-03-26 |
| Robert C. Gray | 男 | Director | 78 | 7.75万美元 | 0.30 | 2026-03-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert A. Berman | 男 | Chief Executive Officer and Director | 63 | 58.38万美元 | 4.58 | 2026-03-26 |
| Marc H. Glickman | 男 | Chief Medical Officer and Senior Vice President | 76 | 43.24万美元 | 2.38 | 2026-03-26 |
| Hamed Alavi | 男 | Chief Technology Officer and Senior Vice President | 42 | 34.22万美元 | 1.86 | 2026-03-26 |
| Jennifer Bright | 女 | Chief Financial Officer | 55 | 117.26万美元 | 0.33 | 2026-03-26 |
董事简历
中英对照 | 中文 | 英文- Robert A. Berman
-
Robert A. Berman自2018年4月起担任enVVeno Medical医疗集团首席执行官、enVVeno Medical公司董事会成员。2012年9月至2017年7月，担任IT公司（现称Anixa Biosciences）总裁、首席执行官、董事会成员，该公司当时他加入的公司是一家平板显示技术研发商，并在他的领导下成为纳斯达克上市的癌症治疗公司。从2000年到2007年3月，Berman先生担任Acacia Research Corporation的首席运营官和总法律顾问，在那里他成功地将公司从一家互联网初创公司的孵化器转变为一家卓越的专利技术许可和执行上市公司，市值超过20亿美元。Berman先生的职业生涯始于Blank Rome律师事务所。Berman先生拥有宾夕法尼亚大学沃顿商学院的创业管理学士学位，并拥有Northstern大学法学院的法学博士学位，他是该学院的兼职教员。
Robert A. Berman has served as Chief Executive Officer and a member of Board of Directors since April of 2018. Mr. Berman has over 25 years of experience in a broad variety of areas including healthcare, finance, acquisitions, marketing, compliance, turnarounds, and the development and licensing of emerging technologies. From September 2012 until July 2017, he served as the President, Chief Executive Officer, and a member of the Board of Directors of IT Corporation (now called Anixa Biosciences), which at the time he joined the company was a developer of flat panel display technologies, and under his leadership became a Nasdaq listed cancer therapeutics company. From 2000 to March 2007, Mr. Berman was the Chief Operating Officer and General Counsel of Acacia Research Corporation, where he successfully transitioned the company from being an incubator of internet startups into a preeminent, publicly traded company for licensing and enforcing patented technologies with a market cap exceeding $2 billion. Mr. Berman started his career at the law firm of Blank Rome. Mr. Berman has a B.S. in Entrepreneurial Management from the Wharton School of the University of Pennsylvania and holds a J.D. from the Northstern University School of Law, where he is an adjunct faculty member. - Robert A. Berman自2018年4月起担任enVVeno Medical医疗集团首席执行官、enVVeno Medical公司董事会成员。2012年9月至2017年7月，担任IT公司（现称Anixa Biosciences）总裁、首席执行官、董事会成员，该公司当时他加入的公司是一家平板显示技术研发商，并在他的领导下成为纳斯达克上市的癌症治疗公司。从2000年到2007年3月，Berman先生担任Acacia Research Corporation的首席运营官和总法律顾问，在那里他成功地将公司从一家互联网初创公司的孵化器转变为一家卓越的专利技术许可和执行上市公司，市值超过20亿美元。Berman先生的职业生涯始于Blank Rome律师事务所。Berman先生拥有宾夕法尼亚大学沃顿商学院的创业管理学士学位，并拥有Northstern大学法学院的法学博士学位，他是该学院的兼职教员。
- Robert A. Berman has served as Chief Executive Officer and a member of Board of Directors since April of 2018. Mr. Berman has over 25 years of experience in a broad variety of areas including healthcare, finance, acquisitions, marketing, compliance, turnarounds, and the development and licensing of emerging technologies. From September 2012 until July 2017, he served as the President, Chief Executive Officer, and a member of the Board of Directors of IT Corporation (now called Anixa Biosciences), which at the time he joined the company was a developer of flat panel display technologies, and under his leadership became a Nasdaq listed cancer therapeutics company. From 2000 to March 2007, Mr. Berman was the Chief Operating Officer and General Counsel of Acacia Research Corporation, where he successfully transitioned the company from being an incubator of internet startups into a preeminent, publicly traded company for licensing and enforcing patented technologies with a market cap exceeding $2 billion. Mr. Berman started his career at the law firm of Blank Rome. Mr. Berman has a B.S. in Entrepreneurial Management from the Wharton School of the University of Pennsylvania and holds a J.D. from the Northstern University School of Law, where he is an adjunct faculty member.
- Francis Duhay
-
Francis Duhay自2018年10月以来一直担任我们的董事会成员。一名训练有素的心脏和胸部外科医生，自2016年以来一直担任心脏附件设备制造商Aegis Surgical Inc.和Atrius Inc.的总裁兼首席运营官，并自2017年以来担任早期风险基金K5_Ventures的合伙人。Duhay博士是爱德华兹生命科学公司（Edwards Life Sciences）的前首席医疗官，该公司是心脏瓣膜产品的世界领导者，在那里他领导了经导管和外科心脏瓣膜的医疗和临床事务。在Edwards Life Sciences任职期间，从2008年到2016年，Duhay博士领导了两项FDA上市前批准的经导管和外科心脏瓣膜疗法PMA申请的准备和提交以及最终监管批准，并负责设计和执行适用的临床试验。杜海博士也是爱德华兹公司Ascendra™；经导管心脏瓣膜业务部的Vice President和总经理，在那里他将该部门的员工从16人增加到80人，并为年销售额从300万美元增加到2.5亿美元做出了贡献。从1998年到2003年，Duhay博士担任Kaiser Permanente的心胸外科与心脏病学系主任。Duhay博士还担任过行业代表和临床专家，以及ISO5840（心脏瓣膜设计、开发和测试的国际质量标准）的工作组成员。Duhay博士在夏威夷大学希德勒商学院（University of Hawaii-Shidler College of Business）获得工商管理硕士学位，并分别在杜克大学医学院（Duke University School of Medicine）和加州大学旧金山分校（University of California，San Francisco）获得心胸外科和普通外科的董事会认证。
Francis Duhay has served as member of board of directors since October 2018. He is an accomplished heart surgeon, entrepreneur, and corporate executive. Board certified in general (UCSF) and cardiothoracic surgery (Duke), his seminal work in minimally invasive cardiac surgery led to 32 patents for surgical devices ed in thoands of heart operations. Dr Duhay left clinical practice for indtry in 2008, where he served as Vice President and General Manager of the nascent transcatheter heart valve therapy program (Ascendra) at Edwards Lifesciences ("Edwards"), the world's leading manufacturer of bioprosthetic heart valves. With European CE Mark, he oversaw growth in sales of transcatheter heart valves from $3M to over $250M within the first f years of commercial launch. Promoted to Vice President of Global Medical & Clinical Affairs, he led planning and execution of f U.S. FDA pivotal clinical trials. He was eventually promoted to Chief Medical Officer, where, in addition to overseeing Global Medical & Clinical Affairs, he supported other areas within Edwards including Health Economics & Reimbursement in its successful application for a procedure code, payment, and coverage of transcatheter aortic valve replacement (TAVR), and Regulatory Affairs, as an indtry representative and clinical expert on the ISO 5840:2014 and 5910:2018 cardiac valve working groups. After departing Edwards, he co founded and led Koa Accel, a major medical device accelerator in the Orange County, CA, ecosystem. This bore three medical device startups – Makani Science (selected into the 2021 cohort of the prestigio Y Combinator), Kino Discovery (selected into the 2021 cohort of MedTech Innovator), and Kahala Biosciences. Most recently, Dr Duhay served as Senior Vice President of Global Medical & Clinical Affairs for Olymp Corporation, the world's leading manufacturer of colonoscopes, duodenoscopes, bronchoscopes, and cystoscopes. - Francis Duhay自2018年10月以来一直担任我们的董事会成员。一名训练有素的心脏和胸部外科医生，自2016年以来一直担任心脏附件设备制造商Aegis Surgical Inc.和Atrius Inc.的总裁兼首席运营官，并自2017年以来担任早期风险基金K5_Ventures的合伙人。Duhay博士是爱德华兹生命科学公司（Edwards Life Sciences）的前首席医疗官，该公司是心脏瓣膜产品的世界领导者，在那里他领导了经导管和外科心脏瓣膜的医疗和临床事务。在Edwards Life Sciences任职期间，从2008年到2016年，Duhay博士领导了两项FDA上市前批准的经导管和外科心脏瓣膜疗法PMA申请的准备和提交以及最终监管批准，并负责设计和执行适用的临床试验。杜海博士也是爱德华兹公司Ascendra™；经导管心脏瓣膜业务部的Vice President和总经理，在那里他将该部门的员工从16人增加到80人，并为年销售额从300万美元增加到2.5亿美元做出了贡献。从1998年到2003年，Duhay博士担任Kaiser Permanente的心胸外科与心脏病学系主任。Duhay博士还担任过行业代表和临床专家，以及ISO5840（心脏瓣膜设计、开发和测试的国际质量标准）的工作组成员。Duhay博士在夏威夷大学希德勒商学院（University of Hawaii-Shidler College of Business）获得工商管理硕士学位，并分别在杜克大学医学院（Duke University School of Medicine）和加州大学旧金山分校（University of California，San Francisco）获得心胸外科和普通外科的董事会认证。
- Francis Duhay has served as member of board of directors since October 2018. He is an accomplished heart surgeon, entrepreneur, and corporate executive. Board certified in general (UCSF) and cardiothoracic surgery (Duke), his seminal work in minimally invasive cardiac surgery led to 32 patents for surgical devices ed in thoands of heart operations. Dr Duhay left clinical practice for indtry in 2008, where he served as Vice President and General Manager of the nascent transcatheter heart valve therapy program (Ascendra) at Edwards Lifesciences ("Edwards"), the world's leading manufacturer of bioprosthetic heart valves. With European CE Mark, he oversaw growth in sales of transcatheter heart valves from $3M to over $250M within the first f years of commercial launch. Promoted to Vice President of Global Medical & Clinical Affairs, he led planning and execution of f U.S. FDA pivotal clinical trials. He was eventually promoted to Chief Medical Officer, where, in addition to overseeing Global Medical & Clinical Affairs, he supported other areas within Edwards including Health Economics & Reimbursement in its successful application for a procedure code, payment, and coverage of transcatheter aortic valve replacement (TAVR), and Regulatory Affairs, as an indtry representative and clinical expert on the ISO 5840:2014 and 5910:2018 cardiac valve working groups. After departing Edwards, he co founded and led Koa Accel, a major medical device accelerator in the Orange County, CA, ecosystem. This bore three medical device startups – Makani Science (selected into the 2021 cohort of the prestigio Y Combinator), Kino Discovery (selected into the 2021 cohort of MedTech Innovator), and Kahala Biosciences. Most recently, Dr Duhay served as Senior Vice President of Global Medical & Clinical Affairs for Olymp Corporation, the world's leading manufacturer of colonoscopes, duodenoscopes, bronchoscopes, and cystoscopes.
- Sanjay Shrivastava
-
Sanjay Shrivastava自2018年10月以来一直担任我们的董事会成员。他参与医疗设备的开发、商业化、评估和收购已超过18年，包括在几家医疗设备初创企业担任首席执行官和董事会职务，以及在研究与开发、业务发展方面担任领导职务，以及2017年至2018年在首旅美敦力（2007年至2017年），雅培血管（2003年至2007年）和爱德华兹生命科学（2000年至2003年）的营销。他目前是U.S.Vascular，LLC的营销和业务发展Vice President，也是BlackSwan Vascular，Inc.的联合创始人和董事会成员。Shrivastava博士在首旅集团（BTG）担任Vice President、上游营销和战略工作期间，参与了几项收购和投资交易。首旅集团是一家医疗设备和专业制药公司，年收入约为8亿美元。在Medtronic，Shrivastava博士是心脏和血管集团的全球营销总监，在那里他帮助建立栓塞业务，在六年的时间里从初创到拥有非常高的CAGR的可观收入。Shrivastava博士是Abbott Vascular公司负责外周血管业务的研究与开发经理，也是Edwards Life Sciences公司负责经导管心脏瓣膜的首席研究与开发工程师。Shrivastava博士在印度理工学院（Indian Institute of Technology）获得工程学理学士学位，并在佛罗里达大学（University of Florida）获得材料科学与工程哲学博士学位。
Sanjay Shrivastava has served as a member of board of directors since October 2018. He has been involved in developing, commercializing, evaluating, and acquiring medical devices for more than 24 years, including serving in leadership positions in research and development, biness development, and marketing at J&J, BTG, plc, Medtronic, Abbott Vascular, and Edwards Life Sciences. He is presently serving as the chief executive officer at Innova Vascular, Inc., an early commercial stage medical device company engaged in peripheral veno thrombectomy space. Prior to this, he co founded BlackSwan Vascular, Inc., where he served on its board of directors and led a strategic alliance including the acquisition deal with Sirtex Medical. Sirtex Medical's parent company acquired BlackSwan Vascular, Inc. in 2023. Dr. Shrivastava worked on several acquisition and investment deals during his roles as a senior director, biness development at J&J and a vice president, upstream marketing and strategy at BTG, plc, which had an annual revenue of about $800 million and is now part of Boston Scientific Corporation through an acquisition. At Medtronic, Dr. Shrivastava was the Director of Global Marketing for the Cardiac and Vascular Group where he helped build the embolization biness, from its initiation to a substantial revenue with a very high CAGR over a period of six (6) years. Dr. Shrivastava was part of the peripheral vascular biness at Abbott Vascular and worked on trans catheter heart valve repair and replacement products at Edwards Life Sciences. Dr. Shrivastava received his Bachelor of Engineering degree at the Indian Institute of Technology and a doctorate degree in materials science and engineering from the University of Florida. - Sanjay Shrivastava自2018年10月以来一直担任我们的董事会成员。他参与医疗设备的开发、商业化、评估和收购已超过18年，包括在几家医疗设备初创企业担任首席执行官和董事会职务，以及在研究与开发、业务发展方面担任领导职务，以及2017年至2018年在首旅美敦力（2007年至2017年），雅培血管（2003年至2007年）和爱德华兹生命科学（2000年至2003年）的营销。他目前是U.S.Vascular，LLC的营销和业务发展Vice President，也是BlackSwan Vascular，Inc.的联合创始人和董事会成员。Shrivastava博士在首旅集团（BTG）担任Vice President、上游营销和战略工作期间，参与了几项收购和投资交易。首旅集团是一家医疗设备和专业制药公司，年收入约为8亿美元。在Medtronic，Shrivastava博士是心脏和血管集团的全球营销总监，在那里他帮助建立栓塞业务，在六年的时间里从初创到拥有非常高的CAGR的可观收入。Shrivastava博士是Abbott Vascular公司负责外周血管业务的研究与开发经理，也是Edwards Life Sciences公司负责经导管心脏瓣膜的首席研究与开发工程师。Shrivastava博士在印度理工学院（Indian Institute of Technology）获得工程学理学士学位，并在佛罗里达大学（University of Florida）获得材料科学与工程哲学博士学位。
- Sanjay Shrivastava has served as a member of board of directors since October 2018. He has been involved in developing, commercializing, evaluating, and acquiring medical devices for more than 24 years, including serving in leadership positions in research and development, biness development, and marketing at J&J, BTG, plc, Medtronic, Abbott Vascular, and Edwards Life Sciences. He is presently serving as the chief executive officer at Innova Vascular, Inc., an early commercial stage medical device company engaged in peripheral veno thrombectomy space. Prior to this, he co founded BlackSwan Vascular, Inc., where he served on its board of directors and led a strategic alliance including the acquisition deal with Sirtex Medical. Sirtex Medical's parent company acquired BlackSwan Vascular, Inc. in 2023. Dr. Shrivastava worked on several acquisition and investment deals during his roles as a senior director, biness development at J&J and a vice president, upstream marketing and strategy at BTG, plc, which had an annual revenue of about $800 million and is now part of Boston Scientific Corporation through an acquisition. At Medtronic, Dr. Shrivastava was the Director of Global Marketing for the Cardiac and Vascular Group where he helped build the embolization biness, from its initiation to a substantial revenue with a very high CAGR over a period of six (6) years. Dr. Shrivastava was part of the peripheral vascular biness at Abbott Vascular and worked on trans catheter heart valve repair and replacement products at Edwards Life Sciences. Dr. Shrivastava received his Bachelor of Engineering degree at the Indian Institute of Technology and a doctorate degree in materials science and engineering from the University of Florida.
- Matthew M. Jenusaitis
-
MatthewM.Jenusaitis自2019年9月以来一直担任我们的董事会成员。他拥有30年以上的医疗保健经验，专注于建立和销售开发医疗设备以治疗血管疾病的公司。Jenusaitis自2015年3月起担任UC San Diego Health System参谋长以及创新和转型主管。2009年6月至2015年3月，Jenusaitis先生担任Octane Foundation for Innovation的总裁兼首席执行官，这是一家非营利组织，专注于加利福尼亚州橘子县的创新发展。在他的职业生涯中，Jenusaitis先生一直担任Pulsar Vascular2008-2017（出售给强生），Creagh Medical（2008-2015）（出售给Surmodics）和Precision Wire Components（2009-2014）（出售给Creganna Medical）的董事会成员。Jenusaitis先生还是EV3公司的高级副总裁（2006年4月至2008年7月），该公司被出售给Covidian公司，后来被Medtronics公司收购。此外，Jenusaitis先生是Boston Scientific外围部门的总裁（2003年7月至2005年8月），是Warburg Pincus的常驻高管（2005年9月至2006年3月）。Jenusaitis先生拥有加州大学欧文分校（University of California，Irvine）工商管理硕士学位，亚利桑那州立大学（Arizona State University）生物医学工程硕士学位，以及康奈尔大学（Cornell University）化学工程学士学位。
Matthew M. Jenusaitis has served as a member of board of directors since September 2019. He has over 30 years of health care experience with an emphasis on building and selling companies that develop medical devices to treat vascular diseases. Since March 2015, Mr. Jenusaitis has been a senior administrative executive at the UC San Diego Health System. He currently serves as the Chief Administrative Officer for UCSD's Moore's Cancer Center and UCSD Oncology. From June 2009 to March 2015, Mr. Jenusaitis was President and CEO of OCTANe Foundation for Innovation, a non profit foced on the development of innovation in Orange County, CA. Over the cse of his career, Mr. Jenusaitis has been on the board of directors of Pulsar Vascular (2008 2017), which was sold to Johnson and Johnson, Creagh Medical (2008 2015), which was sold to SurModics, and Precision Wire Components (2009 2014), which was sold to Creganna Medical. Mr. Jenusaitis was also a Senior Vice President at ev3 (April 2006 to July 2008), which was sold to Covidian and later purchased by Medtronics. In addition, Mr. Jenusaitis was the President of the Peripheral Division at Boston Scientific (July 2003 to Augt 2005) and was an Executive in Residence at Warburg Pinc (September 2005 to March 2006). - MatthewM.Jenusaitis自2019年9月以来一直担任我们的董事会成员。他拥有30年以上的医疗保健经验，专注于建立和销售开发医疗设备以治疗血管疾病的公司。Jenusaitis自2015年3月起担任UC San Diego Health System参谋长以及创新和转型主管。2009年6月至2015年3月，Jenusaitis先生担任Octane Foundation for Innovation的总裁兼首席执行官，这是一家非营利组织，专注于加利福尼亚州橘子县的创新发展。在他的职业生涯中，Jenusaitis先生一直担任Pulsar Vascular2008-2017（出售给强生），Creagh Medical（2008-2015）（出售给Surmodics）和Precision Wire Components（2009-2014）（出售给Creganna Medical）的董事会成员。Jenusaitis先生还是EV3公司的高级副总裁（2006年4月至2008年7月），该公司被出售给Covidian公司，后来被Medtronics公司收购。此外，Jenusaitis先生是Boston Scientific外围部门的总裁（2003年7月至2005年8月），是Warburg Pincus的常驻高管（2005年9月至2006年3月）。Jenusaitis先生拥有加州大学欧文分校（University of California，Irvine）工商管理硕士学位，亚利桑那州立大学（Arizona State University）生物医学工程硕士学位，以及康奈尔大学（Cornell University）化学工程学士学位。
- Matthew M. Jenusaitis has served as a member of board of directors since September 2019. He has over 30 years of health care experience with an emphasis on building and selling companies that develop medical devices to treat vascular diseases. Since March 2015, Mr. Jenusaitis has been a senior administrative executive at the UC San Diego Health System. He currently serves as the Chief Administrative Officer for UCSD's Moore's Cancer Center and UCSD Oncology. From June 2009 to March 2015, Mr. Jenusaitis was President and CEO of OCTANe Foundation for Innovation, a non profit foced on the development of innovation in Orange County, CA. Over the cse of his career, Mr. Jenusaitis has been on the board of directors of Pulsar Vascular (2008 2017), which was sold to Johnson and Johnson, Creagh Medical (2008 2015), which was sold to SurModics, and Precision Wire Components (2009 2014), which was sold to Creganna Medical. Mr. Jenusaitis was also a Senior Vice President at ev3 (April 2006 to July 2008), which was sold to Covidian and later purchased by Medtronics. In addition, Mr. Jenusaitis was the President of the Peripheral Division at Boston Scientific (July 2003 to Augt 2005) and was an Executive in Residence at Warburg Pinc (September 2005 to March 2006).
- Robert C. Gray
-
RobertC.Gray自2019年9月以来一直担任我们的董事会成员。他在Highmark，Inc.拥有20年的职业生涯，该公司是美国最大的健康保险组织之一，为2000多万订户服务，包括Highmark Blue Cross Blue Shield Pennsylvania、Highmark Blue Cross Blue Shield Delaware和Highmark Blue Shield West Virginia（他于2008年退休）。在Highmark时，Gray先生帮助将收入从69亿美元增加到123亿美元，并从9100万美元的运营亏损中获得了3.75亿美元的运营收益。除了担任Highmark&；8217；s多家子公司和关联公司的董事会主席、首席执行官和总裁外，格雷先生还是Highmark&；8217；s母公司的首席财务官，也是Highmark&；8217；s审计、投资和薪酬激励计划委员会董事会的主要联系人。他在Highmark的许多职责包括费率制定和报销谈判。继Highmark之后，Gray先生联合创立了U.S.Holdings有限责任公司（U.S.Implants LLC.该公司是骨科植入物的全国经销商，自2009年以来一直担任Vice President。自2011年以来，Gray先生还自谋职业，担任战略和财务顾问。Gray先生在北卡罗莱纳大学教堂山分校（University of North Carolina-Chapel Hill）从事研究生学习，并在巴克内尔大学（Bucknell University）获得本科学位。
Robert C. Gray has served as a member of board of directors since September 2019. He had a tnty (20) year career at Highmark, Inc., one of America's largest health insurance organizations, which serves over 20 million subscribers, and includes Highmark Blue Cross Blue Shield Pennsylvania, Highmark Blue Cross Blue Shield Delaware, and Highmark Blue Cross Blue Shield st Virginia, which he retired from in 2008. While at Highmark, Mr. Gray helped increase revenues to $12.3 billion from $6.9 billion, and helped generate an operating gain of $375 million from an operating loss of $91 million. In addition to being the board chairman, Chief Executive Officer, and President of several of Highmark's subsidiaries and affiliated companies, Mr. Gray was the Chief Financial Officer of Highmark's parent company and was the primary contact to Highmark's board of directors for Highmark's audit, investment and compensation (incentive plans) committees. His many responsibilities at Highmark included rate setting and reimbursement negotiations. Following Highmark, Mr. Gray co founded U.S. Holdings LLC (U.S. Implants LLC.), a national distributor of orthopedic implants, and has served as Vice President since 2009. Since 2011, Mr. Gray has also been self employed as a strategy and financial consultant. Mr. Gray also currently serves as Chairman and President of Metropolitan Woodworks, Inc., a manufacturer of ctom kitchen cabinetry based in North Carolina. - RobertC.Gray自2019年9月以来一直担任我们的董事会成员。他在Highmark，Inc.拥有20年的职业生涯，该公司是美国最大的健康保险组织之一，为2000多万订户服务，包括Highmark Blue Cross Blue Shield Pennsylvania、Highmark Blue Cross Blue Shield Delaware和Highmark Blue Shield West Virginia（他于2008年退休）。在Highmark时，Gray先生帮助将收入从69亿美元增加到123亿美元，并从9100万美元的运营亏损中获得了3.75亿美元的运营收益。除了担任Highmark&；8217；s多家子公司和关联公司的董事会主席、首席执行官和总裁外，格雷先生还是Highmark&；8217；s母公司的首席财务官，也是Highmark&；8217；s审计、投资和薪酬激励计划委员会董事会的主要联系人。他在Highmark的许多职责包括费率制定和报销谈判。继Highmark之后，Gray先生联合创立了U.S.Holdings有限责任公司（U.S.Implants LLC.该公司是骨科植入物的全国经销商，自2009年以来一直担任Vice President。自2011年以来，Gray先生还自谋职业，担任战略和财务顾问。Gray先生在北卡罗莱纳大学教堂山分校（University of North Carolina-Chapel Hill）从事研究生学习，并在巴克内尔大学（Bucknell University）获得本科学位。
- Robert C. Gray has served as a member of board of directors since September 2019. He had a tnty (20) year career at Highmark, Inc., one of America's largest health insurance organizations, which serves over 20 million subscribers, and includes Highmark Blue Cross Blue Shield Pennsylvania, Highmark Blue Cross Blue Shield Delaware, and Highmark Blue Cross Blue Shield st Virginia, which he retired from in 2008. While at Highmark, Mr. Gray helped increase revenues to $12.3 billion from $6.9 billion, and helped generate an operating gain of $375 million from an operating loss of $91 million. In addition to being the board chairman, Chief Executive Officer, and President of several of Highmark's subsidiaries and affiliated companies, Mr. Gray was the Chief Financial Officer of Highmark's parent company and was the primary contact to Highmark's board of directors for Highmark's audit, investment and compensation (incentive plans) committees. His many responsibilities at Highmark included rate setting and reimbursement negotiations. Following Highmark, Mr. Gray co founded U.S. Holdings LLC (U.S. Implants LLC.), a national distributor of orthopedic implants, and has served as Vice President since 2009. Since 2011, Mr. Gray has also been self employed as a strategy and financial consultant. Mr. Gray also currently serves as Chairman and President of Metropolitan Woodworks, Inc., a manufacturer of ctom kitchen cabinetry based in North Carolina.
高管简历
中英对照 | 中文 | 英文- Robert A. Berman
Robert A. Berman自2018年4月起担任enVVeno Medical医疗集团首席执行官、enVVeno Medical公司董事会成员。2012年9月至2017年7月，担任IT公司（现称Anixa Biosciences）总裁、首席执行官、董事会成员，该公司当时他加入的公司是一家平板显示技术研发商，并在他的领导下成为纳斯达克上市的癌症治疗公司。从2000年到2007年3月，Berman先生担任Acacia Research Corporation的首席运营官和总法律顾问，在那里他成功地将公司从一家互联网初创公司的孵化器转变为一家卓越的专利技术许可和执行上市公司，市值超过20亿美元。Berman先生的职业生涯始于Blank Rome律师事务所。Berman先生拥有宾夕法尼亚大学沃顿商学院的创业管理学士学位，并拥有Northstern大学法学院的法学博士学位，他是该学院的兼职教员。
Robert A. Berman has served as Chief Executive Officer and a member of Board of Directors since April of 2018. Mr. Berman has over 25 years of experience in a broad variety of areas including healthcare, finance, acquisitions, marketing, compliance, turnarounds, and the development and licensing of emerging technologies. From September 2012 until July 2017, he served as the President, Chief Executive Officer, and a member of the Board of Directors of IT Corporation (now called Anixa Biosciences), which at the time he joined the company was a developer of flat panel display technologies, and under his leadership became a Nasdaq listed cancer therapeutics company. From 2000 to March 2007, Mr. Berman was the Chief Operating Officer and General Counsel of Acacia Research Corporation, where he successfully transitioned the company from being an incubator of internet startups into a preeminent, publicly traded company for licensing and enforcing patented technologies with a market cap exceeding $2 billion. Mr. Berman started his career at the law firm of Blank Rome. Mr. Berman has a B.S. in Entrepreneurial Management from the Wharton School of the University of Pennsylvania and holds a J.D. from the Northstern University School of Law, where he is an adjunct faculty member.- Robert A. Berman自2018年4月起担任enVVeno Medical医疗集团首席执行官、enVVeno Medical公司董事会成员。2012年9月至2017年7月，担任IT公司（现称Anixa Biosciences）总裁、首席执行官、董事会成员，该公司当时他加入的公司是一家平板显示技术研发商，并在他的领导下成为纳斯达克上市的癌症治疗公司。从2000年到2007年3月，Berman先生担任Acacia Research Corporation的首席运营官和总法律顾问，在那里他成功地将公司从一家互联网初创公司的孵化器转变为一家卓越的专利技术许可和执行上市公司，市值超过20亿美元。Berman先生的职业生涯始于Blank Rome律师事务所。Berman先生拥有宾夕法尼亚大学沃顿商学院的创业管理学士学位，并拥有Northstern大学法学院的法学博士学位，他是该学院的兼职教员。
- Robert A. Berman has served as Chief Executive Officer and a member of Board of Directors since April of 2018. Mr. Berman has over 25 years of experience in a broad variety of areas including healthcare, finance, acquisitions, marketing, compliance, turnarounds, and the development and licensing of emerging technologies. From September 2012 until July 2017, he served as the President, Chief Executive Officer, and a member of the Board of Directors of IT Corporation (now called Anixa Biosciences), which at the time he joined the company was a developer of flat panel display technologies, and under his leadership became a Nasdaq listed cancer therapeutics company. From 2000 to March 2007, Mr. Berman was the Chief Operating Officer and General Counsel of Acacia Research Corporation, where he successfully transitioned the company from being an incubator of internet startups into a preeminent, publicly traded company for licensing and enforcing patented technologies with a market cap exceeding $2 billion. Mr. Berman started his career at the law firm of Blank Rome. Mr. Berman has a B.S. in Entrepreneurial Management from the Wharton School of the University of Pennsylvania and holds a J.D. from the Northstern University School of Law, where he is an adjunct faculty member.
- Marc H. Glickman
MarcH.Glickman自2016年5月起担任我们的高级副总裁兼首席医疗官，并于2016年7月至2017年8月担任我们的董事会成员。1981年，Glickman博士在弗吉尼亚州诺福克开始了血管实践。他在弗吉尼亚州建立了第一个静脉中心，还创建了透析接入中心。他曾任职Sentara Health Care公司，担任血管服务董事，直到2014年退休。Glickman博士是董事会认证的血管外科医生。Glickman博士在俄亥俄州克利夫兰凯斯西储大学（Case Western Reserve）获得医学博士学位，并在西雅图华盛顿大学（University of Washington，Seattle）完成住院医师资格。他是Vascular Surgery的董事会认证，是the Vascular Society of the Americas的前任总裁。他曾任职Possis Medical公司、Cohesion Technologies公司、Thoratec公司、GraftCath，Inc.、TVA Medical公司（位于德克萨斯州奥斯汀）的顾问委员会。
Marc H. Glickman has served as Senior Vice President and Chief Medical Officer since May 2016 and served as member of board of directors from July 2016 to August 2017. In 1981, Dr. Glickman started a vascular practice in Norfolk, Virginia. He established the first Vein Center in Virginia and also created a dialysis access center. He was employed by Sentara Health Care as director of Vascular Services until he retired in 2014. Dr. Glickman is a board certified vascular surgeon. Dr. Glickman received his Doctor of Medicine from Case stern Reserve, in Cleveland, Ohio and completed his residency at the University of Washington, Seattle. He is board certified in Vascular Surgery and was the past president of the Vascular Society of the Americas. He has served on the advisory boards of Possis Medical, Cohesion Technologies, Thoratec, GraftCath, Inc., TVA medical, Atin, Texas.- MarcH.Glickman自2016年5月起担任我们的高级副总裁兼首席医疗官，并于2016年7月至2017年8月担任我们的董事会成员。1981年，Glickman博士在弗吉尼亚州诺福克开始了血管实践。他在弗吉尼亚州建立了第一个静脉中心，还创建了透析接入中心。他曾任职Sentara Health Care公司，担任血管服务董事，直到2014年退休。Glickman博士是董事会认证的血管外科医生。Glickman博士在俄亥俄州克利夫兰凯斯西储大学（Case Western Reserve）获得医学博士学位，并在西雅图华盛顿大学（University of Washington，Seattle）完成住院医师资格。他是Vascular Surgery的董事会认证，是the Vascular Society of the Americas的前任总裁。他曾任职Possis Medical公司、Cohesion Technologies公司、Thoratec公司、GraftCath，Inc.、TVA Medical公司（位于德克萨斯州奥斯汀）的顾问委员会。
- Marc H. Glickman has served as Senior Vice President and Chief Medical Officer since May 2016 and served as member of board of directors from July 2016 to August 2017. In 1981, Dr. Glickman started a vascular practice in Norfolk, Virginia. He established the first Vein Center in Virginia and also created a dialysis access center. He was employed by Sentara Health Care as director of Vascular Services until he retired in 2014. Dr. Glickman is a board certified vascular surgeon. Dr. Glickman received his Doctor of Medicine from Case stern Reserve, in Cleveland, Ohio and completed his residency at the University of Washington, Seattle. He is board certified in Vascular Surgery and was the past president of the Vascular Society of the Americas. He has served on the advisory boards of Possis Medical, Cohesion Technologies, Thoratec, GraftCath, Inc., TVA medical, Atin, Texas.
- Hamed Alavi
Hamed Alavi于2020年7月加入enVVeno Medical，担任研究、发展和质量总监，并于2021年1月晋升为研究、发展和质量副总裁。在加入enVVeno Medical之前，Alavi博士是NaviGate Cardiac Structures Inc.的工程主管，该公司是一家开发三尖瓣置换和输送系统装置的公司，并曾在美敦力心脏和血管集团（CVG）和爱德华兹生命科学先进心血管技术中心任职，在那里他培养了自己的技术和领导技能，以推动早期医疗设备技术从构想到商业化。Alavi博士在加州大学欧文分校获得生物医学工程博士学位，在那里他接受了美国最著名的心血管工程博士项目之一的培训。他在杂交组织和可植入医疗设备方面的开创性工作得到了许多机构的广泛认可和赞誉——例如美国心脏协会。他还拥有生物医学工程学硕士学位和机械工程学学士学位。
Hamed Alavi joined enVVeno Medical as Director, Research, Development and Quality in July 2020 and was promoted to Vice President of Research, Development and Quality in January 2021. Prior to joining enVVeno Medical, Dr. Alavi was the head of engineering at NaviGate Cardiac Structures Inc., a company which developed tricpid heart valve replacement and delivery system devices, and held roles at Medtronic Cardiac and Vascular Group (CVG) and Edwards Lifesciences Center for Advanced Cardiovascular Technology where he ed his technical and leadership skills to drive early stage medical device technologies from conception to commercialization. Dr. Alavi received his doctorate in biomedical engineering from the University of California, Irvine where he was trained in one of the most prominent cardiovascular engineering doctoral programs in the . His pioneering work in hybrid tissue and implantable medical devices was broadly recognized and given accolades by a number of institutions – such as the American Heart Association. He also holds an M.S. degree in biomedical engineering and a B.S. degree in mechanical engineering.- Hamed Alavi于2020年7月加入enVVeno Medical，担任研究、发展和质量总监，并于2021年1月晋升为研究、发展和质量副总裁。在加入enVVeno Medical之前，Alavi博士是NaviGate Cardiac Structures Inc.的工程主管，该公司是一家开发三尖瓣置换和输送系统装置的公司，并曾在美敦力心脏和血管集团（CVG）和爱德华兹生命科学先进心血管技术中心任职，在那里他培养了自己的技术和领导技能，以推动早期医疗设备技术从构想到商业化。Alavi博士在加州大学欧文分校获得生物医学工程博士学位，在那里他接受了美国最著名的心血管工程博士项目之一的培训。他在杂交组织和可植入医疗设备方面的开创性工作得到了许多机构的广泛认可和赞誉——例如美国心脏协会。他还拥有生物医学工程学硕士学位和机械工程学学士学位。
- Hamed Alavi joined enVVeno Medical as Director, Research, Development and Quality in July 2020 and was promoted to Vice President of Research, Development and Quality in January 2021. Prior to joining enVVeno Medical, Dr. Alavi was the head of engineering at NaviGate Cardiac Structures Inc., a company which developed tricpid heart valve replacement and delivery system devices, and held roles at Medtronic Cardiac and Vascular Group (CVG) and Edwards Lifesciences Center for Advanced Cardiovascular Technology where he ed his technical and leadership skills to drive early stage medical device technologies from conception to commercialization. Dr. Alavi received his doctorate in biomedical engineering from the University of California, Irvine where he was trained in one of the most prominent cardiovascular engineering doctoral programs in the . His pioneering work in hybrid tissue and implantable medical devices was broadly recognized and given accolades by a number of institutions – such as the American Heart Association. He also holds an M.S. degree in biomedical engineering and a B.S. degree in mechanical engineering.
- Jennifer Bright
Jennifer Bright自2025年5月起担任enVVeno Medical Corporation 首席财务官。Bright女士是一名注册会计师，拥有超过25年的专业会计和财务经验。Bright女士曾是BIOLASE，Inc.的首席财务官，直到2024年11月该公司将几乎所有资产出售给MegaGenImplant Co.，LTD。2020年6月至2020年12月，她在光谱制药担任临时会计总监，并于2018年11月至2020年4月在Kellermeyer Bergensons Services担任公司控制人。Previoly，Bright女士曾在Advantage Solutions，Inc.、Crunch Holdings，LLC、Apria Healthcare Group，Inc.、Richmond American Homes担任高级会计总监和控制人职务，曾任普华永道会计师事务所会计师事务所的监事高级审计师。Bright女士拥有华盛顿大学Biness Administration学士学位。
Jennifer Bright has served as Chief Financial Officer since May 2025. Ms. Bright is a certified public accountant with more than 25 years of professional accounting and finance experience. Ms. Bright was the Chief Financial Officer of BIOLASE, Inc., until November 2024 when the company sold substantially all assets to MegaGen Implant Co., LTD. From June 2020 to December 2020, she was consulting as Interim Director of Accounting at Spectrum Pharmaceuticals and was the Corporate Controller at Kellermeyer Bergensons Services from November 2018 to April 2020. Previoly, Ms. Bright held senior accounting director and controller positions at Advantage Solutions, Inc., Crunch Holdings, LLC, Apria Healthcare Group, Inc., and Richmond American Homes, and was a Supervising Senior Auditor at the accounting firm of PricewaterhoeCoopers LLP. Ms. Bright holds a B.A. degree in Biness Administration from the University of Washington.- Jennifer Bright自2025年5月起担任enVVeno Medical Corporation 首席财务官。Bright女士是一名注册会计师，拥有超过25年的专业会计和财务经验。Bright女士曾是BIOLASE，Inc.的首席财务官，直到2024年11月该公司将几乎所有资产出售给MegaGenImplant Co.，LTD。2020年6月至2020年12月，她在光谱制药担任临时会计总监，并于2018年11月至2020年4月在Kellermeyer Bergensons Services担任公司控制人。Previoly，Bright女士曾在Advantage Solutions，Inc.、Crunch Holdings，LLC、Apria Healthcare Group，Inc.、Richmond American Homes担任高级会计总监和控制人职务，曾任普华永道会计师事务所会计师事务所的监事高级审计师。Bright女士拥有华盛顿大学Biness Administration学士学位。
- Jennifer Bright has served as Chief Financial Officer since May 2025. Ms. Bright is a certified public accountant with more than 25 years of professional accounting and finance experience. Ms. Bright was the Chief Financial Officer of BIOLASE, Inc., until November 2024 when the company sold substantially all assets to MegaGen Implant Co., LTD. From June 2020 to December 2020, she was consulting as Interim Director of Accounting at Spectrum Pharmaceuticals and was the Corporate Controller at Kellermeyer Bergensons Services from November 2018 to April 2020. Previoly, Ms. Bright held senior accounting director and controller positions at Advantage Solutions, Inc., Crunch Holdings, LLC, Apria Healthcare Group, Inc., and Richmond American Homes, and was a Supervising Senior Auditor at the accounting firm of PricewaterhoeCoopers LLP. Ms. Bright holds a B.A. degree in Biness Administration from the University of Washington.